Tetanus in injecting drug users

British Medical Journal

Volumn 330, Issue 7485, 2005, Pages 208-209

  Beeching, Nick J ^a   Crowcroft, Natasha S ^b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIAMORPHINE; MAGNESIUM; MORPHINE; TETANUS ANTIBODY;

BOTULISM; CLINICAL FEATURE; CLOSTRIDIUM; CLOSTRIDIUM BOTULINUM; CLOSTRIDIUM NOVYI; DIAGNOSTIC ACCURACY; DIAPHRAGM PARALYSIS; DIFFERENTIAL DIAGNOSIS; DIPLOPIA; DYSARTHRIA; DYSPHAGIA; EARLY DIAGNOSIS; EDITORIAL; FLACCID PARALYSIS; HIGH RISK POPULATION; HUMAN; INTRAVENOUS DRUG ABUSE; JOINT STIFFNESS; MUSCLE SPASM; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; SWEATING; SYMPTOM; TETANUS; TETANUS PROPHYLAXIS; UNITED KINGDOM;

EID: 13244299230     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.330.7485.208     Document Type: Editorial

References (14)

1. Bellis MA, Beynon C, Millar T, Ashton JR, Thomson R, Djuretic T, et al. Unexplained illness and deaths among injecting drug users in England: a case-control study using regional drug misuse databases. J Epidemiol Community Health 2001;55:843-4.
2. Health Protection Agency. Increased reports of suspected cases of wound botulism among injecting drug users during 2004. Commun Dis Rep CDR Wkly 2004;14(35):26 Aug. www.hpa.org.uk/cdr/PDFfiles/2004/cdr3504. pdf (accessed 26 Aug 2004).
3. Passaro DJ, Werner SB, McGee J, MacKenzie WR, Vugia DJ. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998;279:859-63.
4. Tetanus after hypodermic injection of morphia. Lancet 1876;ii:873.
5. Levinson A, Marske RL, Shein MK. Tetanus in heroin addicts. JAMA 1955;157:658-60.
6. Cherubin CE. Epidemiology of tetanus in narcotic addicts. N Y State J Med 1970;70:267-71.
7. Pascual FB, McGinley EL, Zanardi LR, Cortese MM, Murphy TV. Tetanus surveillance-United States, 1998-2000. Morb Mortal Wkly Rep MMWR 2003;52(SS-3):1-12. www.cdc.gov/mmwr/preview/mmwhtml/ss5203a1. htm (accessed 10 Aug 2004).
8. Rushdy AA, White JM, Ramsay ME, Crowcroft NS. Tetanus in England and Wales, 1984-2000. Epidemiol Infect 2003;130:71-7.
9. Health Protection Agency. Ongoing national outbreak of tetanus in injecting drug users. Commun Dis Rep CDR Wkly 2004;14(9):26 Feb. www.hpa.org.uk/cdr/PDFfiles/2004/cdr0904.pdf (accessed 8 Aug 2004).
10. Vermeer-de Bondt P, Vos LP. Tetanus in an injecting drug user in the Netherlands: single case so far. Eurosurveill Wkly 2004;8(19):6 May. www.eurosurveillance.org/ew/2004/040506.asp (accessed 8 August 2004).
11. Cook TM, Protheroe RT, Handel JM. Tetanus: a review of the literature. Br J Anaesthes 2001;87:477-87.
12. Farrar JJ, Yen LM, Cook T, Fairweather N, Binh N, Parry J, Parry CM. Tetanus. J Neurol Neurosurg Psychiatry 2000;69:292-301.
13. British Medical Association, Royal Pharmaceutical Society of Great Britain. British national formulary. London: BMA, RPS, 2004:596. (No 47.)
14. Miranda-Filho D de B, Ximenes RA de A, Barone AA, Vaz VL, Vieria AG, Albuquerque VMG. Randomised controlled trial of tetanus treatment with antitetanus immunoglobulin by the intrathecal or intramuscular route. BMJ 2004;328:615-7.